Stockscreener 앱 받기
18.55
0.70%
-0.13
시간 외 거래:
19.59
1.04
+5.61%
전일 마감가:
$18.68
열려 있는:
$18.73
하루 거래량:
244.89K
Relative Volume:
0.57
시가총액:
$939.97M
수익:
$62.02M
순이익/손실:
$-45.65M
주가수익비율:
-20.16
EPS:
-0.92
순현금흐름:
$-9.60M
1주 성능:
-8.62%
1개월 성능:
+24.08%
6개월 성능:
+72.24%
1년 성능:
+88.52%
1일 변동 폭
$18.48
$18.85
1주일 범위
$18.39
$20.24
52주 변동 폭
$7.90
$20.33
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
18.55 | 947.57M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-12 | 개시 | B. Riley Securities | Buy |
| 2024-08-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 개시 | BTIG Research | Buy |
| 2024-01-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 개시 | Cowen | Outperform |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 개시 | H.C. Wainwright | Buy |
| 2018-03-29 | 재개 | Piper Jaffray | Overweight |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-12-21 | 개시 | Needham | Buy |
| 2016-11-03 | 개시 | Piper Jaffray | Overweight |
| 2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 개시 | Guggenheim | Buy |
| 2016-06-20 | 재확인 | Leerink Partners | Outperform |
| 2016-05-12 | 개시 | Leerink Partners | Outperform |
| 2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect? - Zacks Investment Research
How Theravance Biopharma Inc. (0TB) stock reacts to fiscal policiesBond Market & Long-Term Safe Investment Plans - Newser
Why Theravance Biopharma Inc. (0TB) stock attracts HNW investorsJuly 2025 Price Swings & Advanced Technical Analysis Signals - Newser
Is Theravance Biopharma Inc. stock ready for breakoutEarnings Performance Report & Free Real-Time Market Sentiment Alerts - Newser
Oppenheimer Initiates Coverage of Theravance Biopharma (TBPH) with Outperform Recommendation - Nasdaq
VP Farnum Files To Sell 31,067 Of Theravance Biopharma Inc [TBPH] - TradingView
Oppenheimer Initiates Coverage on TBPH with Outperform Rating | - GuruFocus
Oppenheimer Initiates Theravance Biopharma at Outperform With $27 Price Target - marketscreener.com
Oppenheimer initiates Theravance Biopharma stock with Outperform rating - Investing.com
Oppenheimer initiates Theravance Biopharma stock with Outperform rating By Investing.com - Investing.com Canada
Market Trends: Will Theravance Biopharma Inc stock maintain momentum in 2025July 2025 Spike Watch & Consistent Return Investment Signals - BỘ NỘI VỤ
Why analysts recommend Theravance Biopharma Inc. (0TB) stockWeekly Profit Report & Growth Focused Investment Plans - Newser
Will Theravance Biopharma Inc. stock maintain momentum in 20252025 AllTime Highs & Accurate Trade Setup Notifications - Newser
Dir Broshy Sells 29,501 ($590K) Of Theravance Biopharma Inc [TBPH] - TradingView
Trading Systems Reacting to (TBPH) Volatility - news.stocktradersdaily.com
Theravance Biopharma stock hits 52-week high at 20.29 USD By Investing.com - Investing.com Nigeria
How Theravance Biopharma Inc. stock reacts to global recession fearsTrade Volume Report & Risk Managed Investment Signals - moha.gov.vn
Theravance Biopharma stock hits 52-week high at 20.29 USD - Investing.com
Aug Movers: Will Theravance Biopharma Inc. stock outperform Dow Jones index2025 Geopolitical Influence & Short-Term High Return Ideas - BỘ NỘI VỤ
Why Theravance Biopharma Inc. stock could outperform in 2025Weekly Risk Report & Daily Chart Pattern Signal Reports - BỘ NỘI VỤ
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up Following Analyst Upgrade - MarketBeat
Theravance Biopharma, Inc. $TBPH Shares Acquired by Jefferies Financial Group Inc. - MarketBeat
BTIG Maintains Theravance Biopharma (TBPH) Buy Recommendation - MSN
Dir Broshy Files To Sell 29,501 Of Theravance Biopharma Inc [TBPH] - TradingView
TBPH: BTIG Raises Price Target to $40 While Maintaining Buy Rati - GuruFocus
Theravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month HighHere's What Happened - MarketBeat
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity - Stock Titan
CFO Sawaf Surrenders 18,627 Of Theravance Biopharma Inc [TBPH] - TradingView
TBPH insider filing: CFO tax-withholding of 18,627 shares at $17.90 - Stock Titan
VP Miller Surrenders 6,989 Of Theravance Biopharma Inc [TBPH] - TradingView
VP Farnum Surrenders 9,060 Of Theravance Biopharma Inc [TBPH] - TradingView
Theravance's Q3 Earnings Surpass Estimates, Revenues Match - MSN
CEO Winningham Surrenders 56,817 Of Theravance Biopharma Inc [TBPH] - TradingView
Can Theravance Biopharma Inc. stock beat analyst upgrades - newser.com
Why pension funds invest in Theravance Biopharma Inc. (0TB) stock2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Is Theravance Biopharma Inc. stock attractive for passive investors2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy? - MSN
Why Theravance Biopharma Inc. stock is rated strong buy2025 Fundamental Recap & Accurate Trade Setup Notifications - newser.com
Theravance Biopharma to host virtual KOL event on ampreloxetine study By Investing.com - Investing.com Nigeria
Theravance Biopharma to host virtual KOL event on ampreloxetine study - Investing.com
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - 富途牛牛
Is Theravance Biopharma Inc. (0TB) stock a fit for income portfoliosJuly 2025 Review & Technical Analysis for Trade Confirmation - newser.com
Theravance Biopharma Inc. stock trendline breakdownQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.44%
0.91%
자본화:
|
볼륨(24시간):